This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.

We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our collective immunology and translational discovery and development expertise serves as the foundation of our company. We are pursuing product candidates with strong scientific rationale to address indications where there is both a high unmet need and an opportunity to develop best-in-class or first-in-class programs.

discovery
phase 1
phase 2
phase 3
GB001
DP2 antagonist – moderate to severe eosinophilic asthma. Phase 2b ongoing.
GB001
DP2 antagonist – chronic rhinosinusitis. Phase 2 ongoing.
GB001
DP2 antagonist – chronic spontaneous urticaria. Phase 2 planned.
GB002
PDGF receptor kinase inhibitor - pulmonary arterial hypertension. Phase 1 ongoing.
GB004
HIF-1a stabilizer – Inflammatory Bowel Disease. Phase 1 ongoing.
GB1275
CD11b agonist. Preclinical program.
Autoimmune Program
Preclinical program